Short-Course Radiotherapy is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Tianjin Medical University Cancer Institute and Hospital (1). The most-studied condition is Advanced Rectal Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer
NCT07281157 · ClinicalTrials.gov ↗ · Advanced Rectal Cancer
|
Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | China |
|
Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study
NCT07663071 · ClinicalTrials.gov ↗ · Rectal Cancer Patients
|
Phase 2 | Active, closed | Harbin Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Harbin Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Short-Course Radiotherapy as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tianjin Medical University Cancer Institute and Hospital (1) and Harbin Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Short-Course Radiotherapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Short-Course Radiotherapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Short-Course Radiotherapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.